Hidradenitis Suppurativa – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hidradenitis Suppurativa – Drugs In Development, 2024 report and make more profitable business decisions.
Hidradenitis suppurativa (HS) is a chronic skin condition that features pea- to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop in areas where skin rubs together, such as the armpits, groin, between the buttocks, and under the breasts.
The Hidradenitis Suppurativa drugs in development market research report provide comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hidradenitis Suppurativa | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 47 molecules, with 47 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hidradenitis Suppurativa therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hidradenitis Suppurativa pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hidradenitis Suppurativa treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAccro Bioscience Suzhou Co Ltd
Acelyrin Inc
Amgen Inc
Azora Therapeutics Australia Pty Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Citryll BV
CSL Ltd
Eli Lilly and Co
Henlez
Incyte Corp
Inmagene Biopharmaceuticals Ltd
Innovation Pharmaceuticals Inc
Innovent Biologics Inc
Insmed Inc
Johnson & Johnson
Jubilant Therapeutics Inc
Kymab Ltd
Kymera Therapeutics Inc
Lanleys International Inc
MC2 Therapeutics AS
MoonLake Immunotherapeutics
NeuClone Pty Ltd
NovaRock Biotherapeutics Inc
Novartis AG
Pfizer Inc
Pharma Holdings AS
Pharmapraxis
Phoenicis Therapeutics Inc
Priovant Therapeutics Inc
Rigel Pharmaceuticals Inc
Sandoz Group AG
Scinai Immunotherapeutics Ltd
Shanghai Lingtai Biomedical Technology Co Ltd
Sonoma Biotherapeutics Inc
Staidson BioPharma Inc
UCB SA
Union Therapeutics AS
Zura Bio Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hidradenitis Suppurativa reports